AR
Fagron N.V.
ARSUF · OTC
$27.50 +0.00% (+$0.00)
Market Cap 1.73B €
P/E Ratio 19.06x
Div. Yield 1.69%
ROE 16.95%
Bulios Fair Price
$40.78
48.3% upside
Current Price
$27.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ARSUF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
73 /100
Cheap P/E 19.06x
P/FCF 15.35x
EV/EBITDA 10.71x
Growth
65 /100
Stable EPS growth 8.91%
Book val. growth 11.05%
Rev. growth 11.65%
Profitability
58 /100
Moderate Gross margin 15.25%
FCF margin 11.87%
Net margin 9.56%
Quality
68 /100
Excellent ROIC 10.99%
Asset turnover 0.77x
ROE 16.95%
Debt
66 /100
Moderate Debt/Equity 0.93x
Net debt/EBITDA 1.70x
Current ratio 2.11x
Stability
87 /100
Stable Beta 0.39x
Profitable years 6
Rev. volatility 2.56%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ARSUF
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Rafael Padilla
Employees
4,134
Headquarters
Nazareth
Upcoming events
18 FEB
Earnings
Upcoming earnings report